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A 29‐year‐old man was diagnosed with a clinical stage IIIB nonseminomatous germ cell tumor of the testis (NSGCT). He presented with an elevated alpha‐fetoprotein level of 4533 and a retroperitoneal mass measuring 22 cm. After frontline chemotherapy comprising bleomycin, etoposide, and cisplatin (BEP) ×4, pathologic examination from a RPLND and left orchiectomy showed less than 5% teratoma with extensive necrosis in the residual lymph node.

No recurrence or metastasis was found by a CT performed 7 months later (Figure [1](#ccr32476-fig-0001){ref-type="fig"}). After complaints of abdominal pain, nausea, vomiting, and early satiety, one month later, a CT scan showed a mass with a thick rim (Figure [2](#ccr32476-fig-0002){ref-type="fig"}). Differential diagnoses include fibrosarcoma, Burkitt lymphoma, and parasitic abscess. Biopsy revealed embryonal carcinoma.

![Representative image from an abdominal CT scan on 05/06/2013 showed no evidence of new mass lesion or local recurrence](CCR3-7-2285-g001){#ccr32476-fig-0001}

![Representative image from an abdominal CT scan on 06/24/2013 showed a large, recurrent, partially necrotic abdominal pelvic mass with a thick rim (arrows)](CCR3-7-2285-g002){#ccr32476-fig-0002}

After salvage chemotherapy comprising paclitaxel, ifosfamide, and cisplatin (TIP) ×1 and paclitaxel, doxorubicin, cisplatin (ATP) ×3, resection of the residual mass unveiled multiple minute microscopic foci of NSGCT. Four years after receiving adjuvant chemotherapy comprising TIP ×2, the patient is doing well without evidence of metastatic or recurrent disease.

To our knowledge, this is the first report of a rapidly enlarging mass in a patient with embryonal carcinoma that recurred over 7 weeks. It is highly unusual even for an isolated embryonic tumor to grow in this manner at this rate.[1](#ccr32476-bib-0001){ref-type="ref"}, [2](#ccr32476-bib-0002){ref-type="ref"} For men with relapsed NSGCT, a multimodality approach of chemotherapy combined with resection of all residual disease is the standard of care. Although the overall cure rate is high (\>90%), early detection still offers the best potential for successful treatment.
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